托法替布治疗对司库奇尤单抗抵抗的掌跖银屑病一例  

Palmoplantar psoriasis resistant to secukinumab successfully treated with tofacitinib:a case report

作　　者：崔寅玲 郑淳之 于咏梅 刘红[1,2] CUI Yinling;ZHENG Chunzhi;YU Yongmei;LIU Hong(Hospital for Skin Diseases,Shandong First Medical University,Jinan 250022,China;Shandong Provincial Institute of Dermatology and Venereology,Shandong Academy of Medical Sciences,Jinan 250022,China)

机构地区：[1]山东第一医科大学附属皮肤病医院,山东济南250022 [2]山东省皮肤病性病防治研究所,山东济南250022

出　　处：《中国麻风皮肤病杂志》2024年第2期134-136,共3页China Journal of Leprosy and Skin Diseases

基　　金：山东省皮肤性病学临床医学研究中心。

摘　　要：掌跖银屑病是一种斑块型银屑病少见的亚型,容易漏诊和误诊,传统治疗往往效果不佳,IL-17拮抗剂作为生物制剂在掌跖银屑病疗效良好,但部分患者存在疗效衰减、剂量依赖及不能耐受的现象。JAK抑制剂通过抑制JAK-STAT通路,影响一系列细胞因子的功能,发挥免疫调节作用。本文报道1例用JAK抑制剂托法替布治疗司库奇尤单抗抵抗的掌跖银屑病,并取得良好的疗效。Palmoplantar psoriasis is a rare phenotype of plaque psoriasis that is easy to miss and misdiagnose,and traditional treatments are often ineffective.IL-17 inhibitors are effective as biologics in palmoplantar psoriasis,but there is attenuation of efficacy,dose dependence,and intolerability in some patients.JAK inhibitors could affect a series of cytokines by inhibiting the JAK-STAT pathway,and play an immunomodulatory role.In this paper,we report a case of palmoplantar psoriasis resistant to secukinumab treated with JAK inhibitor tofacitinib,and achieved good results.

关 键 词：托法替布 掌跖银屑病 JAK抑制剂 IL-17拮抗剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]